Biobetters market seen reaching $121.61 billion by 2030

Nov. 20, 2026
Biobetters market seen reaching $121.61 billion by 2030
By AI, Created 17:15 UTC, Nov 20, 2026, AGP -

The biobetters market is projected to grow from $75.29 billion in 2025 to $121.61 billion by 2030, driven by rising chronic and autoimmune disease cases, drug delivery innovation and wider use of improved biologics. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Biobetters are designed to improve on existing biologics with better dosing, fewer side effects, stronger stability or easier administration. - Those upgrades matter because they can improve patient outcomes while addressing limits in older biologic therapies. - Demand is rising as chronic disease and autoimmune disease prevalence increases worldwide.

What happened: - The biobetters market reached $75.29 billion in 2025. - The market is forecast to rise to $83.84 billion in 2026, a 11.4% CAGR. - The market is projected to reach $121.61 billion by 2030, with a 9.7% CAGR. - The forecast comes from The Business Research Company’s Biobetters Global Market Report 2026.

The details: - Market growth through 2026 is tied to chronic disease prevalence, biosimilar awareness, biotechnology advances, supportive government policy and an aging population. - Growth through 2030 is linked to broader adoption of biobetters over original biologics. - Drug delivery innovation, expanding healthcare infrastructure in emerging markets and strategic biopharmaceutical collaborations are also expected to support demand. - Personalized medical treatment is another driver behind projected adoption. - The report points to improved effectiveness and safety, optimized dosing, better stability and shelf life, easier administration and wider chronic disease use as key trends. - Chronic kidney disease is a major demand driver because the condition is becoming more common as populations age and diabetes and hypertension increase. - Oxford Academic research published in June 2023 said CKD prevalence in the UK is expected to rise 4%, from 0.00827 billion in 2022 to 0.00861 billion by 2032. - Autoimmune diseases are also boosting demand because biobetters can offer more stable formulations, better dosing and fewer adverse effects than original biologics. - The September 2023 Impact of IBD Report from the IBD Clinical and Research Centre in Canada said inflammatory bowel disease affected 825 per 100,000 people, or more than 0.00032 billion individuals. - That report projected IBD prevalence could reach 0.00047 billion by 2035. - North America held the largest biobetters market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The market outlook suggests biobetters are moving from a niche improvement on biologics toward a broader role in long-term disease management. - The strongest demand signals come from conditions that require ongoing treatment, where convenience and durability can matter as much as efficacy. - The regional split suggests mature demand in North America and faster expansion in markets still building healthcare capacity.

What's next: - More growth will likely depend on how quickly biobetters gain adoption over original biologics across chronic and autoimmune disease treatment. - Expansion in emerging markets could become a bigger driver as healthcare infrastructure improves. - Further clinical and delivery innovations are likely to shape product development and competition.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Asia News Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Asia News Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.